These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7154786)

  • 1. [Amphetamine in the therapy of hyperactivity in children].
    Scholander T
    Lakartidningen; 1982 Dec; 79(50):4759-61. PubMed ID: 7154786
    [No Abstract]   [Full Text] [Related]  

  • 2. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of hyperactivity and attention deficit with amphetamine. Experience with five adult prisoners].
    Stovner AM; Wyller TB; Skulberg A; Os L; Korsmo G
    Tidsskr Nor Laegeforen; 1996 Jun; 116(17):2002-5. PubMed ID: 8766640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letter: Stimulant drugs for problem children.
    N Engl J Med; 1973 Dec; 289(25):1375-6. PubMed ID: 4201792
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorder.
    Donner R; Michaels MA; Ambrosini PJ
    Biol Psychiatry; 2007 Mar; 61(5):706-12. PubMed ID: 16899230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug therapy of minimal brain dysfunction syndrome (clinical study using Captagon)].
    Mangold B
    Prax Kinderpsychol Kinderpsychiatr; 1975 Jul; 24(5):185-90. PubMed ID: 1187555
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of ADHD with amphetamine: short-term effects on family interaction.
    Gustafsson P; Hansson K; Eidevall L; Thernlund G; Svedin CG
    J Atten Disord; 2008 Jul; 12(1):83-91. PubMed ID: 17968029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates.
    Ricaurte GA; Mechan AO; Yuan J; Hatzidimitriou G; Xie T; Mayne AH; McCann UD
    J Pharmacol Exp Ther; 2005 Oct; 315(1):91-8. PubMed ID: 16014752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugs for the hyperactive child.
    DiPalma JR
    RN; 1972 May; 35(5):61-9. PubMed ID: 4483480
    [No Abstract]   [Full Text] [Related]  

  • 12. [Apropos the National Board and Welfare's report on ADDH: some views on the treatment with central nervous system stimulants].
    Zetterström R
    Lakartidningen; 2002 Aug; 99(35):3435-6. PubMed ID: 12362770
    [No Abstract]   [Full Text] [Related]  

  • 13. ["The amphetamine treatment helped my child". Is it time to reevaluate Swedish practice in hyperactivity syndrome?].
    Lakartidningen; 1996 Nov; 93(47):4307-8. PubMed ID: 8984302
    [No Abstract]   [Full Text] [Related]  

  • 14. Cerebral dysfunctions-clarification, delineation, classification.
    Block WM
    PDM; 1974; 5-6(9-12;1-8):21-5. PubMed ID: 4464490
    [No Abstract]   [Full Text] [Related]  

  • 15. Adderall XR: long acting stimulant for single daily dosing.
    Sallee FR; Smirnoff AV
    Expert Rev Neurother; 2004 Nov; 4(6):927-34. PubMed ID: 15853519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Amphetamines in the treatment of hyperactive and instable children].
    Glós J
    Cesk Pediatr; 1973 Oct; 28(10):559-60. PubMed ID: 4766681
    [No Abstract]   [Full Text] [Related]  

  • 17. Overweight in children and adolescents in relation to attention-deficit/hyperactivity disorder: results from a national sample.
    Waring ME; Lapane KL
    Pediatrics; 2008 Jul; 122(1):e1-6. PubMed ID: 18595954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on amphetamine neurotoxicity and its relevance to the treatment of ADHD.
    Advokat C
    J Atten Disord; 2007 Jul; 11(1):8-16. PubMed ID: 17606768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Medication for ADHD and the risk of cardiovascular mortality].
    Kalverdijk LJ; Buitelaar JK; van der Gaag RJ
    Ned Tijdschr Geneeskd; 2006 Oct; 150(41):2283-4; author reply 2284. PubMed ID: 17078147
    [No Abstract]   [Full Text] [Related]  

  • 20. Racemic amphetamine sulfate (Evekeo) for ADHD.
    Med Lett Drugs Ther; 2015 Sep; 57(1478):137-8. PubMed ID: 26393827
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.